‘Number of Unanswered Questions’ Remain About Role of Stereotactic Radiation in Metastatic Kidney Cancer

Video

An expert from the University of Texas Southwestern Medical Center questions how providers are currently utilizing stereotactic radiation in the treatment of metastatic kidney cancer.

There are a number of “unanswered questions” regarding the role of stereotactic radiation in the management of metastatic kidney cancer, according to Raquibul Hannan, MD, PhD.

At the 2022 Society for Urologic Oncology (SUO) Annual Meeting, CancerNetwork® spoke with Hannan about his presentation on clinically managing metastatic kidney cancer with the use of stereotactic radiation.

Hannan, a professor in the Department of Radiation Oncology, Urology and Immunology at the University of Texas Southwestern Medical Center in Dallas, said that delaying systemic therapy for oligometastatic disease in favor of stereotactic radiation and ensuring long-term overall survival among patients pose questions that he and his institution aim to address with future research.

Transcript:

So, [there are] a number of unanswered questions. All of these patients we're treating with oligometastases, also [have] micro-metastatic disease, [also known as] disease that we cannot see. The real question is: are we doing a favor to this patient by delaying this systemic therapy, where we are allowing these micro-metastases to grow? And in the short term, of course, we are seeing very good local control rates, but in the long run, are we affecting overall survival? That's one of the critical questions, and to answer that question, we recently designed and got approval to do a large, randomized phase 3, non-inferiority study with overall survival as one of the co-primary endpoints, where we will do just that. This is the ECOG-EAH-211-SOLE trial that we are expected to open in the summer of 2023.

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Related Content